Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication

HIV Medicine

Volumn 13, Issue 9, 2012, Pages 517-525

  Delaugerre, C ^a   Braun, J ^b   Charreau, I ^b   Delarue, S ^a   Nere, M L ^a   de Castro, N ^a   May, T ^c   Marchou, B ^d   Simon, F ^a   Molina, J M ^a   Aboulker, J P ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c CHU NANCY BRABOIS   (France)

^d CHU PURPAN   (France)

Author keywords

Controlled viraemia; Drug resistance; HIV 1; HIV 1 DNA proviral; Plasma HIV 1 RNA

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE MUTATION; GENOTYPING TECHNIQUE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESISTANCE MUTATION PATTERN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; VIREMIA; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; RNA, VIRAL; VIRUS REPLICATION;

EID: 84866169476     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01002.x     Document Type: Article

References (36)

1. Eron JJ, Young B, Cooper DA etal. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396-407.
2. Bi X, Gatanaga H, Ida S etal. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr 2003; 34: 1-6.
3. Lambotte O, Chaix ML, Gubler B etal. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004; 18: 1147-1158.
4. Ruff CT, Ray SC, Kwon P etal. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002; 76: 9481-9492.
5. Verhofstede C, Noe A, Demecheleer E etal. Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35: 473-483.
6. Wang YM, Dyer WB, Workman C, Wang B, Sullivan JS, Saksena NK. Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART. AIDS 2000; 14: 2265-2272.
7. Turriziani O, Andreoni M, Antonelli G. Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection. Clin Microbiol Infect 2010; 16: 1518-1524.
8. De Castro N, Braun J, Charreau I etal. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009; 49: 1259-1267.
9. Descamps D, Delaugerre C, Masquelier B etal. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006; 78: 153-160.
10. Devereux HL, Loveday C, Youle M, Sabin CA, Burke A, Johnson M. Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. AIDS Res Hum Retroviruses 2000; 16: 1025-1030.
11. Turriziani O, Bucci M, Stano A etal. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr 2007; 44: 518-524.
12. Wirden M, Soulie C, Valantin MA etal. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother 2011; 66: 709-712.
13. Palmisano L, Galluzzo CM, Giuliano M. The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51: 233-234.
14. Izopet J, Marchou B, Charreau I etal. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response. Antivir Ther 2008; 13: 537-545.
15. Palmer S, Kearney M, Maldarelli F etal. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43: 406-413.
16. Paolucci S, Baldanti F, Campanini G etal. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment- naive and HAART patients. J Med Virol 2001; 65: 207-217.
17. Flandre P, Descamps D, Morand-Joubert L etal. Comparison of the use of last genotype versus all past genotypes to classify HIV-1 infected patients according to resistance algorithms. 12th European AIDS Conference/EACS Cologne, Germany, November 2009 [Abstract 14/2].
18. Delaugerre C, Valantin MA, Mouroux M etal. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 2001; 15: 2189-2191.
19. Devereux HL, Loveday C, Youle M, Sabin CA, Burke A, Johnson MA. Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients. J Infect Dis 2000; 181: 1804-1807.
20. Hance AJ, Lemiale V, Izopet J etal. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001; 75: 6410-6417.
21. Izopet J, Souyris C, Hance A etal. Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis 2002; 185: 1506-1510.
22. Poveda E, Briz V, Paraskevis D, Barreiro P, Hatzakis A, Soriano V. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. AIDS Res Hum Retroviruses 2007; 23: 1078-1082.
23. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73: 3744-3752.
24. Mulder LC, Harari A, Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A 2008; 105: 5501-5506.
25. Diaz RS, Accetturi CA, Sucupira MC. Emergence of resistance mutations preceding virologic failure in patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49: 111-113.
26. Pellegrin I, Caumont A, Garrigue I etal. Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 2003; 187: 38-46.
27. Wind-Rotolo M, Durand C, Cranmer L etal. Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis 2009; 199: 1301-1309.
28. Jourdain G, Ngo-Giang-Huong N, Le Coeur S etal. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351: 229-240.
29. Lockman S, Shapiro RL, Smeaton LM etal. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356: 135-147.
30. Wagner TA, Kress CM, Beck I etal. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol 2010; 48: 1555-1561.
31. Ellis GM, Page LC, Burman BE, Buskin S, Frenkel LM. Increased detection of HIV-1 drug resistance at time of diagnosis by testing viral DNA with a sensitive assay. J Acquir Immune Defic Syndr 2009; 51: 283-289.
32. Kabamba-Mukadi B, Duquenne A, Henrivaux P etal. HIV-1 proviral resistance mutations: usefulness in clinical practice. HIV Med 2010; 11: 483-492.
33. Delaugerre C, Marcelin AG, Soulie C etal. Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey. AIDS 2007; 21: 1365-1367.
34. Delaugerre C, Morand-Joubert L, Chaix ML etal. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004; 9: 415-421.
35. Ghosn J, Pellegrin I, Goujard C etal. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20: 159-170.
36. Little SJ, Frost SD, Wong JK etal. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82: 5510-5518.